Senior Director, FasterCures, Milken Institute Health
Kristin Schneeman is a senior director on the FasterCures team at Milken Institute Health. With the Milken Institute since 2005, her primary responsibility is FasterCures' innovation portfolio of projects and activities.
COVID-19 has focused the public’s attention on the racial and ethnic disparities in health outcomes, unequal access to health care, and some communities’ lack of trust and participation in medical research. These problems have been decades, if not centuries, in the making, and they cannot be quickly or easily solved. However, attention is a critical prerequisite to action, and FasterCures believes that we must seize this moment to make real change, particularly to transform the way that local institutions conduct clinical research so that it is representative of the diverse communities comprising the American population.
Examples certainly exist of clinical research networks that have succeeded in increasing the engagement and participation of underserved communities. Many local health-care institutions, however, lack the resources and infrastructure to engage in research, resulting in less robust trials for sponsors, lower access to innovation, and poorer outcomes across communities. COVID-19 revealed in stark terms the price to be paid for the lack of a comprehensive community-based research system that can generate evidence to answer a broad range of critical research questions, whether in the context of sponsor-driven product development trials, comparative effectiveness studies, or a fast-moving public health emergency (PHE).
Ideally, such a nationwide system would find participants in all the places they live and access their care, not just the large academic medical centers where much clinical research is currently conducted. Yet, who should be responsible for creating and maintaining such a system? What steps can the federal government take to build capacity at the local level—to create an “ecosystem of excellence” rather than “islands of pilots”? Building on findings from FasterCures’ 'Lessons Learned from COVID-19: Are There Silver Linings for Biomedical Innovation?' report and a virtual leadership roundtable held in September 2021, this issue brief:
Highlights best practices from organizations that are leading the way in community-based clinical research;
Identifies common infrastructure gaps that exist at the community level and how we can build engaged, interoperable health systems in research moving forward; and
Pinpoints national policies and resources needed to strengthen critical infrastructure at the community level to empower local institutions to participate in clinical research.
FasterCures, a Center of the Milken Institute, is pleased to see the inclusion of $1 billion in funding for a new Advanced Research Projects Agency for Health (ARPA-H) in the omnibus FY22 spending bill recently passed. We have long...
Esther Krofah is the executive vice president of Milken Institute Health, leading FasterCures, Public Health, the Future of Aging, and Feeding Change. She has extensive experience managing efforts to unite diverse stakeholders to solve critical issues and achieve shared goals that improve patients’ lives.
Alzheimer’s disease is increasingly in the spotlight after a number of high-profile clinical trial failures—an alarming trend as an estimated 5.5 million adult Americans live with this disease, which disproportionally affects the aged...
September 17, 2024 (Washington, DC) —The Milken Institute Science Philanthropy Accelerator for Research and Collaboration (SPARC), in partnership with the Ann Theodore Foundation, today announced that more than $2.4 million in funding is...
Paul Guequierre is the director of strategic communications. In this role, he works to increase the profile of Milken Institute in the media, raise the visibility of issues important to the organization and its stakeholders, and expand the Institute's digital presence.
WASHINGTON, DC — FasterCures, a center of the Milken Institute, commends the U.S. Senate on today’s strong, bipartisan support of the 21st Century Cures Act (H.R. 34), which passed the Senate on a 94-5 vote, matching the U.S. House of...
Submitted electronically Division of Dockets Management (HFA-305) Food and Drug Administration Docket No: FDA-2022-N-2394 5630 Fishers Lane Room 1061 Rockville, MD 20852 Re: FDA CBER OTAT Public Patient-Focused Drug Development Listening...
Managing Director, FasterCures, Milken Institute Health
Sung Hee Choe is the managing director on the FasterCures team at the Milken Institute. She oversees the programmatic portfolio and is responsible for day-to-day operations.
Type 1 diabetes, or T1D, once commonly known as juvenile diabetes, is an autoimmune disease in which the immune system attacks the insulin-producing cells of the pancreas. The disease affects people of all ages and causes numerous negative...
The new multimedia feature highlights the 10 vaccines currently in clinical trials. Washington, D.C. – June 11, 2020 – The Milken Institute, the nonprofit, nonpartisan think tank, and First Person, a San Francisco design and storytelling...
The United States—as of June 2020—has more reported cases of COVID-19 than any other country in the world, despite having many of the same resources as other countries that curbed the pandemic more successfully. COVID-19 has highlighted the...
If the objective of biomedical research is to spur innovation to create healthier communities, extend life, and more effectively treat or cure disease, then persistent inequities run counter to that goal and create unnecessary barriers to...
Dear Commissioner Hahn: FasterCures appreciates the opportunity to provide comments to the Food and Drug Adminstration’s (FDA’s) request for comments on the reauthorization of the Medical Device User Fee Act (MDUFA). We applaud the...
More than 500,000 people in the US suffer from bladder cancer. At the time of this report, it was the fifth most common cancer in the US. It is also the most expensive cancer to treat and frequently reoccurs. Despite the fact that the...
Neurodegenerative diseases (ND), including Alzheimer’s disease, Parkinson’s disease, frontotemporal dementia, and others, affect over 50 million people worldwide. The World Health Organization estimates that by the year 2040, NDs will be...